Lung Therapeutics breathes easy with $14M series B

The cash will go toward its early-stage work on two candidates.

Texas startup Lung Therapeutics has got off a $14.3 million series B round as it eyes the cash boost for its trials in fibrosis, lung injury and disease.

Specifically, the new proceeds will help fund its experimental phase 1 therapy LTI-01 in Australia and New Zealand to treat empyema and complicated parapneumonic effusions (CPE), two complications of pneumonia that can involve fibrinous scarring.

It will also go toward what the biotech dubs its “transformative” drug for fibrosis, LTI-03, which is currently in a preclinical stage and targeting idiopathic pulmonary fibrosis, as well as other fibrotic diseases including scleroderma, kidney and cardiac fibrosis.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

This series B brings its total external funds raised to $17 million, building on the $27M in non-dilutive funding awarded for discovery research and development for both drug candidates.

The latest round was led by Bios Partners, a life sciences private equity firm based in Dallas/Fort Worth, with existing investor, the UT Horizon Fund, also taking part.

“We are pursuing unique, proprietary treatments that eliminate the need for surgery and ineffective off-label drugs for patients with loculated pleural effusion as well as new drugs for fibrosis indications such as idiopathic pulmonary fibrosis, scleroderma and cardiac fibrosis,” said Brian Windsor, Ph.D, Lung Therapeutics CEO.

“This brings new hope to a global patient population whose only treatment options are currently limited and expensive. We aim to create better therapeutic options for these and other underserved, life-threatening lung and fibrosis conditions.”

Suggested Articles

The FDA has cleared its first duodenoscope designed to make the intricate, moving and difficult-to-clean parts in the head of the device disposable.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.